ZA976592B - Formulation - Google Patents
FormulationInfo
- Publication number
- ZA976592B ZA976592B ZA976592A ZA976592A ZA976592B ZA 976592 B ZA976592 B ZA 976592B ZA 976592 A ZA976592 A ZA 976592A ZA 976592 A ZA976592 A ZA 976592A ZA 976592 B ZA976592 B ZA 976592B
- Authority
- ZA
- South Africa
- Prior art keywords
- formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9615628.6A GB9615628D0 (en) | 1996-07-25 | 1996-07-25 | Formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA976592B true ZA976592B (en) | 1999-03-04 |
Family
ID=10797487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA976592A ZA976592B (en) | 1996-07-25 | 1997-07-24 | Formulation |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0918521B1 (de) |
| JP (1) | JP2000515868A (de) |
| KR (1) | KR20000029523A (de) |
| CN (1) | CN1226163A (de) |
| AR (1) | AR007983A1 (de) |
| AT (1) | ATE224711T1 (de) |
| BR (1) | BR9710546A (de) |
| CA (1) | CA2261233A1 (de) |
| CO (1) | CO5031290A1 (de) |
| CZ (1) | CZ22799A3 (de) |
| DE (1) | DE69715878T2 (de) |
| DK (1) | DK0918521T3 (de) |
| ES (1) | ES2184121T3 (de) |
| GB (1) | GB9615628D0 (de) |
| IL (1) | IL128095A (de) |
| NO (1) | NO990283L (de) |
| NZ (1) | NZ333704A (de) |
| PL (1) | PL331283A1 (de) |
| PT (1) | PT918521E (de) |
| TR (1) | TR199900141T2 (de) |
| TW (1) | TW426514B (de) |
| WO (1) | WO1998004258A1 (de) |
| ZA (1) | ZA976592B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815383D0 (en) * | 1998-07-15 | 1998-09-16 | Smithkline Beecham Plc | Novel method of treatment |
| CN1221516C (zh) * | 2000-09-27 | 2005-10-05 | Dsmip财产有限公司 | 共轭二烯羰基化的方法 |
| GB0428170D0 (en) * | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Mono and Combination Therapy |
| CN109988144B (zh) | 2017-12-29 | 2024-07-05 | 广州再极医药科技有限公司 | 芳香乙烯或芳香乙基类衍生物、其制备方法、中间体、药物组合物及应用 |
| WO2026018154A1 (en) | 2024-07-16 | 2026-01-22 | Syremis Therapeutics Ltd. | Combinations of sabcomeline with non-cns penetrant muscarinic antagonists |
| WO2026018155A1 (en) | 2024-07-16 | 2026-01-22 | Syremis Therapeutics Ltd. | Combinations of sabcomeline with long-acting non-cns penetrant muscarinic antagonists |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG48315A1 (en) * | 1989-04-13 | 1998-04-17 | Beecham Group Plc | Novel compounds |
| MX9300875A (es) * | 1992-02-20 | 1993-08-31 | Smithkline Beecham Plc | Procedimiento para la preparacion de compuestos azabiciclicos. |
| GB9409705D0 (en) * | 1994-05-14 | 1994-07-06 | Smithkline Beecham Plc | Novel compounds |
| DE19501022C1 (de) * | 1995-01-14 | 1996-06-05 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Verabreichung von (s)-3-Methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazol oder einem seiner pharmazeutisch akzeptablen Salze und Verfahren zu seiner Herstellung |
-
1996
- 1996-07-25 GB GBGB9615628.6A patent/GB9615628D0/en active Pending
-
1997
- 1997-07-14 DK DK97934492T patent/DK0918521T3/da active
- 1997-07-14 TR TR1999/00141T patent/TR199900141T2/xx unknown
- 1997-07-14 EP EP97934492A patent/EP0918521B1/de not_active Expired - Lifetime
- 1997-07-14 CZ CZ99227A patent/CZ22799A3/cs unknown
- 1997-07-14 JP JP10508451A patent/JP2000515868A/ja active Pending
- 1997-07-14 IL IL12809597A patent/IL128095A/en not_active IP Right Cessation
- 1997-07-14 PL PL97331283A patent/PL331283A1/xx unknown
- 1997-07-14 AT AT97934492T patent/ATE224711T1/de not_active IP Right Cessation
- 1997-07-14 CA CA002261233A patent/CA2261233A1/en not_active Abandoned
- 1997-07-14 BR BR9710546A patent/BR9710546A/pt unknown
- 1997-07-14 WO PCT/EP1997/003872 patent/WO1998004258A1/en not_active Ceased
- 1997-07-14 CN CN97196687A patent/CN1226163A/zh active Pending
- 1997-07-14 ES ES97934492T patent/ES2184121T3/es not_active Expired - Lifetime
- 1997-07-14 NZ NZ333704A patent/NZ333704A/en unknown
- 1997-07-14 PT PT97934492T patent/PT918521E/pt unknown
- 1997-07-14 KR KR1019997000576A patent/KR20000029523A/ko not_active Ceased
- 1997-07-14 DE DE69715878T patent/DE69715878T2/de not_active Expired - Fee Related
- 1997-07-23 AR ARP970103327A patent/AR007983A1/es unknown
- 1997-07-24 ZA ZA976592A patent/ZA976592B/xx unknown
- 1997-07-24 TW TW086110515A patent/TW426514B/zh not_active IP Right Cessation
- 1997-07-25 CO CO97042583A patent/CO5031290A1/es unknown
-
1999
- 1999-01-22 NO NO990283A patent/NO990283L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69715878D1 (de) | 2002-10-31 |
| EP0918521A1 (de) | 1999-06-02 |
| CZ22799A3 (cs) | 1999-06-16 |
| DK0918521T3 (da) | 2003-02-03 |
| AU3768497A (en) | 1998-02-20 |
| KR20000029523A (ko) | 2000-05-25 |
| IL128095A (en) | 2002-07-25 |
| BR9710546A (pt) | 1999-08-17 |
| ES2184121T3 (es) | 2003-04-01 |
| DE69715878T2 (de) | 2003-05-22 |
| CN1226163A (zh) | 1999-08-18 |
| AU721101B2 (en) | 2000-06-22 |
| TW426514B (en) | 2001-03-21 |
| NZ333704A (en) | 2000-06-23 |
| WO1998004258A1 (en) | 1998-02-05 |
| TR199900141T2 (xx) | 1999-03-22 |
| CA2261233A1 (en) | 1998-02-05 |
| AR007983A1 (es) | 1999-11-24 |
| NO990283L (no) | 1999-03-19 |
| EP0918521B1 (de) | 2002-09-25 |
| IL128095A0 (en) | 1999-11-30 |
| JP2000515868A (ja) | 2000-11-28 |
| CO5031290A1 (es) | 2001-04-27 |
| HK1021314A1 (en) | 2000-06-09 |
| PT918521E (pt) | 2003-02-28 |
| ATE224711T1 (de) | 2002-10-15 |
| GB9615628D0 (en) | 1996-09-04 |
| NO990283D0 (no) | 1999-01-22 |
| PL331283A1 (en) | 1999-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL135295A0 (en) | 2-methyl-thieno-benzodiazepine formulation | |
| ZA95776B (en) | Novel formulation | |
| ZA9811461B (en) | New formulation | |
| ZA9710601B (en) | Novel formulation | |
| ZA985669B (en) | New formulation | |
| AU131131S (en) | Handleset | |
| GB9724544D0 (en) | Novel Formulation | |
| AU131132S (en) | Handleset | |
| GB9725061D0 (en) | Revitalisation formulation | |
| GB9615628D0 (en) | Formulation | |
| GB9621990D0 (en) | Use | |
| AU131198S (en) | Handleset | |
| AU131199S (en) | Handleset | |
| GB9706957D0 (en) | Formulation | |
| GB9611192D0 (en) | Use | |
| GB9404989D0 (en) | Lipomimetric formulation | |
| HU9602732D0 (en) | Lanperisone formulation | |
| GB9721807D0 (en) | Formulation | |
| GB9725275D0 (en) | Formulation | |
| GB9412641D0 (en) | Formulation | |
| ZA952272B (en) | Formulation | |
| GB9412642D0 (en) | Formulation | |
| GB9416500D0 (en) | Formulation | |
| GB9423416D0 (en) | Formulation | |
| GB9624115D0 (en) | Formulations |